LifeMD (LFMD) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

LFMD Stock Forecast

LifeMD stock forecast is as follows: an average price target of $12.00 (represents a 144.40% upside from LFMD’s last price of $4.91) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

LFMD Price Target

The average price target for LifeMD (LFMD) is $12.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $12.00. This represents a potential 144.40% upside from LFMD's last price of $4.91.

LFMD Analyst Ratings

Buy

According to 5 Wall Street analysts, LifeMD's rating consensus is 'Buy'. The analyst rating breakdown for LFMD stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

LifeMD Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Dec 10, 2024	Brooks O'Neil	Lake Street	$12.00	$5.97	101.01%	144.40%
Oct 14, 2024	Kyle Bauser	BTIG	$12.00	$4.64	158.62%	144.40%
Jun 04, 2024	Steve Dechert	KeyBanc	$12.00	$7.53	59.36%	144.40%
Apr 23, 2024	David Larsen	BTIG	$14.00	$10.00	40.00%	185.13%

The latest LifeMD stock forecast, released on Dec 10, 2024 by Brooks O'Neil from Lake Street, set a price target of $12.00, which represents a 101.01% increase from the stock price at the time of the forecast ($5.97), and a 144.40% increase from LFMD last price ($4.91).

LifeMD Price Target by Period

	1M	3M	12M
# Anlaysts	1	2	4
Avg Price Target	$12.00	$12.00	$12.50
Last Closing Price	$4.91	$4.91	$4.91
Upside/Downside	144.40%	144.40%	154.58%

In the current month, the average price target of LifeMD stock is $12.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 144.40% increase as opposed to LifeMD's last price of $4.91. This month's average price target is down 0.00% compared to last quarter, and down -4.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Dec 10, 2024	Lake Street		Buy	Initialise
Oct 14, 2024	BTIG	Buy	Buy	Hold
Jul 11, 2024	KeyBanc	Overweight	Overweight	Hold
Jun 04, 2024	KeyBanc		Overweight	Initialise
May 21, 2024	B. Riley	Buy	Buy	Hold
May 09, 2024	Cantor Fitzgerald	Overweight	Overweight	Hold
Apr 23, 2024	BTIG	Buy	Buy	Hold
Jul 21, 2023	Cantor Fitzgerald		Overweight	Initialise
May 16, 2022	BTIG	Buy	Buy	Hold

LifeMD's last stock rating was published by Lake Street on Dec 10, 2024. The company Initialise its LFMD rating from "null" to "Buy".

LifeMD Financial Forecast

LifeMD Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	$44.86M	$24.34M	$22.35M	$33.13M	$28.12M	$31.41M	$30.46M	$29.04M	$27.42M	$24.95M	$22.31M	$18.20M	$12.89M
Avg Forecast	$73.57M	$72.93M	$69.20M	$67.38M	$69.13M	$65.98M	$62.74M	$59.25M	$57.47M	$53.82M	$48.46M	$42.59M	$41.30M	$38.44M	$35.15M	$30.81M	$33.58M	$31.85M	$31.31M	$31.53M	$27.46M	$25.28M	$21.78M	$18.22M	$13.26M
High Forecast	$76.73M	$76.07M	$72.18M	$70.28M	$72.10M	$68.82M	$65.44M	$60.55M	$57.62M	$53.87M	$48.46M	$44.42M	$41.45M	$38.58M	$36.66M	$32.13M	$35.02M	$31.85M	$31.31M	$31.53M	$27.46M	$25.28M	$21.78M	$18.22M	$13.26M
Low Forecast	$70.63M	$70.02M	$66.44M	$64.69M	$66.36M	$63.34M	$60.23M	$57.95M	$57.32M	$53.77M	$48.46M	$40.88M	$41.15M	$38.30M	$33.74M	$29.58M	$32.24M	$31.85M	$31.31M	$31.53M	$27.46M	$25.28M	$21.78M	$18.22M	$13.26M
# Analysts	4	4	4	4	3	3	3	5	5	4	1	1	3	1	1	1	1	1	1	1	1	1	1	1	1
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.09%	0.63%	0.64%	1.08%	0.84%	0.99%	0.97%	0.92%	1.00%	0.99%	1.02%	1.00%	0.97%

LifeMD's average Quarter revenue forecast for Mar 24 based on 1 analysts is $42.59M, with a low forecast of $40.88M, and a high forecast of $44.42M. LFMD's average Quarter revenue forecast represents a -5.07% decrease compared to the company's last Quarter revenue of $44.86M (Dec 23).

LifeMD EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
# Analysts	4	4	4	4	3	3	3	5	5	4	1	1	3	1	1	1	1	1	1	1	1	1	1	1	1
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	$-230.81K	$657.22K	$-288.99K	$-1.48M	$-1.92M	$-5.68M	$-12.04M	$-12.58M	$-17.91M	$-12.41M	$-15.63M	$-11.35M	$-31.66M
Avg Forecast	$-31.96M	$-31.69M	$-30.07M	$-29.27M	$-30.03M	$-28.67M	$-27.26M	$-25.74M	$-24.97M	$-23.38M	$-21.05M	$-18.50M	$-17.94M	$-16.70M	$-15.27M	$-13.39M	$-14.59M	$-13.12M	$-12.90M	$-10.04M	$-11.31M	$-10.41M	$-8.97M	$-14.74M	$-5.46M
High Forecast	$-30.68M	$-30.42M	$-28.86M	$-28.10M	$-28.83M	$-27.52M	$-26.17M	$-25.18M	$-24.90M	$-23.36M	$-21.05M	$-17.76M	$-17.88M	$-16.64M	$-14.66M	$-12.85M	$-14.01M	$-13.12M	$-12.90M	$-8.04M	$-11.31M	$-10.41M	$-8.97M	$-11.80M	$-5.46M
Low Forecast	$-33.34M	$-33.05M	$-31.36M	$-30.53M	$-31.32M	$-29.90M	$-28.43M	$-26.31M	$-25.03M	$-23.40M	$-21.05M	$-19.30M	$-18.01M	$-16.76M	$-15.93M	$-13.96M	$-15.22M	$-13.12M	$-12.90M	$-12.05M	$-11.31M	$-10.41M	$-8.97M	$-17.69M	$-5.46M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.01%	-0.04%	0.02%	0.11%	0.13%	0.43%	0.93%	1.25%	1.58%	1.19%	1.74%	0.77%	5.80%

3 analysts predict LFMD's average Quarter EBITDA for Dec 23 to be $-17.94M, with a high of $-17.88M and a low of $-18.01M. This is -2830.02% lower than LifeMD's previous annual EBITDA (Sep 23) of $657.22K.

LifeMD Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
# Analysts	4	4	4	4	3	3	3	5	5	4	1	1	3	1	1	1	1	1	1	1	1	1	1	1	1
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	$-3.73M	$-6.90M	$-7.51M	$-10.08M	$-11.58M	$-8.44M	$-13.09M	$-13.47M	$-18.01M	$-14.35M	$-16.83M	$-11.60M	$-32.25M
Avg Forecast	$3.78M	$3.36M	$3.36M	$3.36M	$2.24M	$60.05K	$-1.26M	$-2.25M	$-2.16M	$-4.97M	$-6.05M	$-6.47M	$-5.88M	$-3.64M	$-3.99M	$-6.72M	$-7.56M	$-8.67M	$-11.56M	$-10.17M	$-15.49M	$-22.92M	$-20.85M	$-15.07M	$-68.14M
High Forecast	$3.99M	$3.55M	$3.55M	$3.55M	$2.37M	$63.41K	$-1.20M	$-2.10M	$-1.08M	$-4.71M	$-5.74M	$-6.14M	$-5.04M	$-3.45M	$-3.78M	$-6.37M	$-7.17M	$-8.67M	$-11.56M	$-8.13M	$-15.49M	$-22.92M	$-20.85M	$-12.05M	$-68.14M
Low Forecast	$3.59M	$3.19M	$3.19M	$3.19M	$2.12M	$56.93K	$-1.33M	$-2.39M	$-2.88M	$-5.25M	$-6.39M	$-6.83M	$-6.30M	$-3.85M	$-4.22M	$-7.10M	$-7.99M	$-8.67M	$-11.56M	$-12.20M	$-15.49M	$-22.92M	$-20.85M	$-18.08M	$-68.14M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.63%	1.89%	1.88%	1.50%	1.53%	0.97%	1.13%	1.32%	1.16%	0.63%	0.81%	0.77%	0.47%

LifeMD's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. LFMD's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

LifeMD SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
# Analysts	4	4	4	4	3	3	3	5	5	4	1	1	3	1	1	1	1	1	1	1	1	1	1	1	1
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	$35.96M	$33.18M	$31.69M	$27.32M	$26.37M	$29.68M	$35.07M	$34.21M	$32.54M	$30.99M	$32.80M	$25.50M	$42.11M
Avg Forecast	$92.76M	$91.96M	$87.26M	$84.96M	$87.16M	$83.20M	$79.11M	$74.71M	$72.46M	$67.86M	$61.10M	$53.70M	$52.07M	$48.47M	$44.32M	$38.85M	$42.34M	$40.16M	$39.48M	$24.71M	$34.63M	$31.87M	$27.47M	$22.97M	$16.71M
High Forecast	$96.75M	$95.92M	$91.01M	$88.61M	$90.91M	$86.77M	$82.51M	$76.35M	$72.65M	$67.92M	$61.10M	$56.01M	$52.26M	$48.65M	$46.23M	$40.52M	$44.16M	$40.16M	$39.48M	$29.65M	$34.63M	$31.87M	$27.47M	$22.97M	$16.71M
Low Forecast	$89.05M	$88.29M	$83.77M	$81.56M	$83.68M	$79.87M	$75.95M	$73.07M	$72.27M	$67.80M	$61.10M	$51.55M	$51.88M	$48.29M	$42.55M	$37.29M	$40.65M	$40.16M	$39.48M	$19.77M	$34.63M	$31.87M	$27.47M	$22.97M	$16.71M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.69%	0.68%	0.71%	0.70%	0.62%	0.74%	0.89%	1.38%	0.94%	0.97%	1.19%	1.11%	2.52%

LifeMD's average Quarter SG&A projection for Mar 24 is $53.70M, based on 1 Wall Street analysts, with a range of $51.55M to $56.01M. The forecast indicates a 49.31% rise compared to LFMD last annual SG&A of $35.96M (Dec 23).

LifeMD EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
# Analysts	4	4	4	4	3	3	3	5	5	4	1	1	3	1	1	1	1	1	1	1	1	1	1	1	1
EPS	-	-	-	-	-	-	-	-	-	-	-	-	$-0.10	$-0.20	$-0.23	$-0.32	$-0.37	$-0.27	$-0.42	$-0.44	$-0.67	$-0.54	$-0.64	$-0.47	$-2.56
Avg Forecast	$0.09	$0.08	$0.08	$0.08	$0.05	-	$-0.03	$-0.05	$-0.05	$-0.12	$-0.14	$-0.15	$-0.14	$-0.09	$-0.10	$-0.16	$-0.18	$-0.21	$-0.28	$-0.29	$-0.38	$-0.56	$-0.51	$-0.38	$-1.65
High Forecast	$0.10	$0.08	$0.08	$0.08	$0.06	-	$-0.03	$-0.05	$-0.03	$-0.11	$-0.14	$-0.15	$-0.12	$-0.08	$-0.09	$-0.15	$-0.17	$-0.21	$-0.28	$-0.29	$-0.38	$-0.56	$-0.51	$-0.38	$-1.65
Low Forecast	$0.09	$0.08	$0.08	$0.08	$0.05	-	$-0.03	$-0.06	$-0.07	$-0.12	$-0.15	$-0.16	$-0.15	$-0.09	$-0.10	$-0.17	$-0.19	$-0.21	$-0.28	$-0.29	$-0.38	$-0.56	$-0.51	$-0.38	$-1.65
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.71%	2.31%	2.42%	2.00%	2.06%	1.29%	1.50%	1.52%	1.79%	0.97%	1.27%	1.24%	1.55%

According to undefined Wall Street analysts, LifeMD's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to LFMD previous annual EPS of $NaN (undefined).

LifeMD Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
CMAX	CareMax	$0.42	$2.20	423.81%	Hold
EVH	Evolent Health	$10.87	$33.00	203.59%	Buy
FORA	Forian	$2.04	$4.50	120.59%	Buy
LFMD	LifeMD	$5.65	$12.00	112.39%	Buy
PRVA	Privia Health Group	$20.79	$23.00	10.63%	Buy
HSTM	HealthStream	$31.97	$29.00	-9.29%	Buy

LFMD Forecast FAQ

Is LifeMD a good buy?

Yes, according to 5 Wall Street analysts, LifeMD (LFMD) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of LFMD's total ratings.

What is LFMD's price target?

LifeMD (LFMD) average price target is $12 with a range of $12 to $12, implying a 144.40% from its last price of $4.91. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will LifeMD stock go up soon?

According to Wall Street analysts' prediction for LFMD stock, the company can go up by 144.40% (from the last price of $4.91 to the average price target of $12), up by 144.40% based on the highest stock price target, and up by 144.40% based on the lowest stock price target.

Can LifeMD stock reach $7?

LFMD's average twelve months analyst stock price target of $12 supports the claim that LifeMD can reach $7 in the near future.

What is LifeMD's current price target trend?

1 Wall Street analyst forecast a $12 price target for LifeMD (LFMD) this month, up 144.40% from its last price of $4.91. Compared to the last 3 and 12 months, the average price target increased by 144.40% and increased by 154.58%, respectively.

What are LifeMD's analysts' financial forecasts?

LifeMD's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $257.1M (high $266.91M, low $247.89M), average EBITDA is $-112M (high $-108M, low $-116M), average net income is $-1.205M (high $-866K, low $-1.54M), average SG&A $324.17M (high $336.54M, low $312.56M), and average EPS is $-0.0287 (high $-0.0206, low $-0.0366). LFMD's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $283.08M (high $295.26M, low $271.77M), average EBITDA is $-123M (high $-118M, low $-128M), average net income is $13.87M (high $14.64M, low $13.15M), average SG&A $356.94M (high $372.29M, low $342.67M), and average EPS is $0.33 (high $0.348, low $0.313).

Did the LFMD's actual financial results beat the analysts' financial forecasts?

Based on LifeMD's last annual report (Dec 2023), the company's revenue was $98.15M, which missed the average analysts forecast of $145.7M by -32.63%. Apple's EBITDA was $5.5M, missing the average prediction of $-63.3M by -108.69%. The company's net income was $-23.702M, beating the average estimation of $-20.24M by 17.11%. Apple's SG&A was $128.15M, missing the average forecast of $183.71M by -30.25%. Lastly, the company's EPS was $-0.7, beating the average prediction of $-0.482 by 45.33%. In terms of the last quarterly report (Dec 2023), LifeMD's revenue was $44.86M, beating the average analysts' forecast of $41.3M by 8.63%. The company's EBITDA was $-231K, missing the average prediction of $-17.942M by -98.71%. LifeMD's net income was $-3.732M, missing the average estimation of $-5.883M by -36.56%. The company's SG&A was $35.96M, missing the average forecast of $52.07M by -30.94%. Lastly, the company's EPS was $-0.1, missing the average prediction of $-0.14 by -28.57%